美第奇新星生物技术(MNOV)
盘后1.51-0.15-9.04%19:59 EDT
1.66+0.47+39.50%
行情数据延迟15分钟
- 最新
- 推荐
暂无内容公司概况
公司名称美第奇新星生物技术所属市场NASDAQ成立日期- -员工人数- -办公地址- -邮政编码- -联系电话- -联系传真- -公司概况MediciNova, Inc.于2000年9月26日在美国特拉华州注册成立。2009年12月，它收购了一家名叫Avigen Inc.的生物制药公司，这家公司专注于寻找和开发差异化的产品来治疗患有严重障碍的病人，公司的候选产品是用于抑制巨噬中枢神经系统内细胞移动和神经胶质衰减器，如神经性疼痛、阿片类药物成瘾和戒断以及甲基苯丙胺成瘾等身体混乱。 MediciNova, Inc.是一家处于发展阶段的生物制药公司，专注于收购和开发新型小分子疗法，治疗美国市场上的严重特殊、但医疗需求未得到满足的疾病。通过战略联盟——主要是与日本制药公司，该公司对一系列多元化的临床和临床前候选产品拥有所有权， 并相信此举能为公司提供重要的商业机会。- 08-22Form S-1 - General form for registration of securities under the Securities Act of 1933招股说明书Form S-1 - General form for registration of securities under the Securities Act of 1933
- 08-14Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-01Form 8-K - Current report重要事件披露Form 8-K - Current report
- 06-18Form 8-K - Current report重要事件披露Form 8-K - Current report
- 05-14Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 03-11Form 8-K - Current report重要事件披露Form 8-K - Current report
- 02-20Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]年度报告Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2024-11-14Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-08Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-06-12Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2024-05-09Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-04-01Form 8-K - Current report重要事件披露Form 8-K - Current report
- 2024-02-15Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]年度报告Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2024-01-20Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments员工持股计划Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 2024-01-20Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments员工持股计划Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
- 分时
- 5日
- 日
- 周
- 月
数据加载中...
最高
1.96
今开
1.36
量比
39.45
最低
1.20
昨收
1.19
换手率
113.11%